These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29870627)

  • 61. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?
    Miller L; Ferreira JA; Tucker C
    J Emerg Med; 2017 Mar; 52(3):341-347. PubMed ID: 27727040
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model.
    Akman N; Braunschweig T; Honickel M; Schütt K; Schöchl H; Stoppe C; Rossaint R; Grottke O
    Br J Anaesth; 2018 May; 120(5):978-987. PubMed ID: 29661415
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reversal of direct oral anticoagulants: a practical approach.
    Shih AW; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
    Tireli D; He J; Nordling MM; Wienecke T
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Severe dabigatran intoxication complicated by insufficient reversal by idarucizumab].
    Hellfritzsch M; Hvas AM
    Ugeskr Laeger; 2020 Apr; 182(15):. PubMed ID: 32286218
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Successful dabigatran reversal after subdural hemorrhage using idarucizumab in a mobile stroke unit: A case report.
    Thirunavukkarasu S; Kalashyan H; Jickling G; Jeerakathil TJ; Jayaprakash HK; Buck BH; Shuaib A; Butcher K
    Medicine (Baltimore); 2020 May; 99(21):e20200. PubMed ID: 32481289
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
    Driesz L; Barabás É; Bodócs I; Szántó Z; Herr G; Bencsik G; Pál L; Borbola J
    Orv Hetil; 2017 Mar; 158(10):387-392. PubMed ID: 28270004
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Use of idarucizumab in clinical practice: a case report].
    Husová L
    Vnitr Lek; 2019; 65(5):377-378. PubMed ID: 31163972
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain.
    Crespo-Leiro MG; López-Vilella R; López Granados A; Mirabet-Pérez S; Díez-López C; Barge-Caballero E; Segovia-Cubero J; González-Vilchez F; Rangel-Sousa D; Blasco-Peiró T; de la Fuente-Galán L; Díaz-Molina B; Zatarain-Nicolás E; Carrasco Ávalos F; Almenar-Bonet L
    Clin Transplant; 2019 Dec; 33(12):e13748. PubMed ID: 31670852
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.
    Quintard H; Viard D; Drici MD; Ruetsch C; Samama CM; Ichai C
    Thromb Haemost; 2017 Jan; 117(1):196-197. PubMed ID: 27734073
    [No Abstract]   [Full Text] [Related]  

  • 72. [A Case of Successful Drug Management with Dabigatran and Idarucizumab to Address Embolic and Hemorrhagic Complications for Asymptomatic and Traumatic Subdural Hematoma with Non-valvular Atrial Fibrillation].
    Nii K; Eto A; Hiraoka F; Tsutsumi M
    No Shinkei Geka; 2018 Nov; 46(11):983-988. PubMed ID: 30458435
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
    Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
    J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Idarucizumab for Intravenous Thrombolysis and Endovascular Thrombectomy in Acute Stroke: A Case Report.
    Lin YT; Lai YJ; Lai TH
    J Emerg Med; 2020 Mar; 58(3):e113-e116. PubMed ID: 31744711
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Persistent life-threatening hemorrhage after administration of idarucizumab.
    Alhashem HM; Avendano C; Hayes BD; Winters ME
    Am J Emerg Med; 2017 Jan; 35(1):193.e3-193.e5. PubMed ID: 27439386
    [No Abstract]   [Full Text] [Related]  

  • 76. Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.
    Grottke O; van Ryn J; Zentai C; Gan G; Honickel M; Rossaint R; Ten Cate H; Spronk HMH
    PLoS One; 2019; 14(1):e0209350. PubMed ID: 30615630
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reversal of dabigatran by idarucizumab: when and how?
    Vanassche T; Greinacher A; Verhamme P
    Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [First new oral anticoagulant with specific antidote].
    Einecke D
    MMW Fortschr Med; 2016 Mar; 158(5):73. PubMed ID: 26979233
    [No Abstract]   [Full Text] [Related]  

  • 79. Idarucizumab for dabigatran overdose in a child.
    Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
    Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
    [No Abstract]   [Full Text] [Related]  

  • 80. Management of epistaxis in patients on novel oral anticoagulation therapy.
    Ho JPK; Bari N; Riffat F
    J Laryngol Otol; 2020 Apr; 134(4):316-322. PubMed ID: 32281535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.